Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.

Expert review of molecular diagnostics - 1 Dec 2019

Ergun Yakup, Acikgoz Yusuf, Bal Oznur, Ucar Gokhan, Dirikoc Merve, Caliskan Yildirim Eda, Akdeniz Nadiye, Uncu Dogan

Abstract excerpt

Background: In this study, we aimed to investigate the frequency, prognostic effect of codon, and amino acid-specific KRAS mutations in patients with metastatic colorectal cancer (mCRC) and their predictive effect on irinotecan and oxaliplatin during first-line treatment.Methods: The data of 304 mCRC patients were retrospectively evaluated between 2010 and 2018. Patients were categorized according to the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Biomarkers, Tumor

Share to Colonic Neoplasms

Share to Irinotecan

Share to Oxaliplatin

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 31718325
DOI: 10.1080/14737159.2019.1693266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.PMID 31718325Read ↗

Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancerSemantic proximity Read ↗

Clinical relevance of KRAS mutations in codon 13: Where are we?Semantic proximity Read ↗

The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.Semantic proximity Read ↗

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.Semantic proximity Read ↗

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.Semantic proximity Read ↗

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value.Semantic proximity Read ↗

KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.Semantic proximity Read ↗

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.Semantic proximity Read ↗

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Semantic proximity Read ↗

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.